Addition to Moberg Pharma’s management team

STOCKHOLM, June 20th, 2018, Moberg Pharma AB (OMX: MOB) announced the appointment of Mark Beveridge as Vice President Finance and member of the management team, effective from July 1st 2018. Mark Beveridge has held various finance positions at Moberg Pharma since 2015 and was previously a senior advisor to the company. 

Mark Beveridge has been appointed Vice President Finance and permanent member of the management team, effective from July 1st 2018. Mark joined Moberg Pharma as a Business Controller in 2015, previously having acted as senior advisor to the company on accounting and ERP issues. Since then, he has been a key member of Moberg’s transaction and finance team. Mark brings extensive experience within system and financial management with a strong background in accounting, assurance and advisory services. Originally from Sydney, Australia, where Mark qualified as a Chartered Accountant, Mark has worked with a broad range of SMEs and publicly listed entities. He was previously a Senior Adviser at Visma Services and held advisory and executive roles in a number of high growth e-commerce platforms, including BuyInvite.com.au (now part of Mysale Group Plc).

”Over the past years, Mark Beveridge has played a key role in Moberg Pharma’s finance and transaction teams. It’s a pleasure to welcome Mark to the management team and I look forward to working together with him to continue developing Moberg Pharma’s operations” says Peter Wolpert, CEO of Moberg Pharma.

About this information
The information was released for public distribution on June 20th 2018 at 11:00 am CET by the contact persons above.

For additional information, please contact:
Peter Wolpert, CEO, telephone: +1 908 432 22 03 (US), +46 70 735 71 35, e-mail: peter.wolpert@mobergpharma.se
Mark Beveridge, VP Finance, telephone: +46 76-805 82 88, e-mail: mark.beveridge@mobergpharma.se

Tags:

About Us

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Contacts

Subscribe

Quotes

Over the past years, Mark Beveridge has played a key role in Moberg Pharma’s finance and transaction teams. It’s a pleasure to welcome Mark to the management team and I look forward to working together with him to continue developing Moberg Pharma’s operations
Peter Wolpert, CEO of Moberg Pharma